NIH SPECIAL SERIES: Testing the efficacy of new cancer treatments/therapies in clinical trials using a unique biomarker

NIH SPECIAL SERIES: Testing the efficacy of new cancer treatments/therapies in clinical trials using a unique biomarker

This webinar has already taken place. However, you can watch a recording of it by clicking on the screen shot just below.

Originally aired on July 30th, 2015

One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH.

Soon, this opportunity to learn directly from a number of NIH scientists, will ONLY be made available to members of our Technology Evaluation Consortium™ (TEC). But, for the next few months, this information is being shared beyond our current membership, to provide you and/or your organization with the opportunity to join the consortium.

This is also your opportunity to participate in our exclusive Signature Square™ process, where end-users rate and evaluate the technology, providing feedback directly to the scientist, to help effect and drive the NIH research Road Map for this technology.

This first NIH opportunity will showcase how a new biomarker technology uniquely measures the progression and aggressiveness of the patient’s cancer. This biomarker also predicts recurrence and metastasis in various cancers, including liver, colorectal, adrenal and lung cancer.

An important application of this biomarker would be its use in clinical trials to better evaluate each patient as to the aggressiveness or progression of their cancer. This is important because this biomarker has shown that some patients who are ‘traditionally’ categorized as Stage 1 cancer, are actually harbouring an underlying disease which is much more aggressive than expected. This could explain why some patients who have been previously-diagnosed as Stage 1 actually have an earlier mortality than expected.

In clinical trials, this biomarker could more effectively stratify the patients who are entered into the clinical trial. And, importantly, over the course of the therapeutic regimen, this biomarker could be utilized to test the responsiveness of the cancer to therapy or treatment.

The applications of this biomarker in clinical trials – could serve to revolutionize oncology clinical trials.

ONCOLOGY CLINICAL TRIALS

This unique partnership with the NIH Office of Technology Transfer allows us to present a novel idea, innovation or research to you, with an aim to increase the partnering and/or licensing opportunities for NIH-developed technologies, by increasing the technologies’ visibility within the life science and healthcare industries. This will serve to further support research, product development, commercialization, and economic development opportunities.

Join us for this exclusive NIH webinar and Signature Square™ evaluation, to know more about this novel application in clinical trials, and to learn about this unique biomarker to test the efficacy of new cancer treatments/therapies.

This biomarker has the potential to revolutionize cancer care by changing the current nomenclature, that is, by going beyond a classification system based on Stages, and now being able to classify cancer according to its aggressiveness.

 

PANELISTS

	SPEAKER: Dr. Peng Loh Principal Senior Investigator NICHD, NIH
	MODERATOR: Dawn Van Dam President & CEO One Million Solutions in Health™